Overview

A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects

Status:
Completed

Trial end date:
2018-04-16

Target enrollment:

Participant gender:

Summary

A Two-Part Phase 1 Study to Investigate A) Safety and Tolerability of Supratherapeutic dose of Zanubrutinib (BGB-3111) and B) Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects

Phase:

Phase 1

Details

Lead Sponsor:

BeiGene

Treatments:

Moxifloxacin
Zanubrutinib